文献速递腹部外周血管CTMR

基于CT和MRI的血管模型诊断临床显著性门脉高压

Diagnosis of Clinically Significant Portal Hypertension Using CT- and MRI-based Vascular Model.
PubMed 文献 · Radiology · 2023-01-31

本研究回顾性纳入肝硬化患者及无肝病对照,从门静脉、肝静脉、主动脉和下腔静脉提取血管参数构建血管几何模型,用于无创诊断临床显著性门脉高压(HVPG≥10 mm Hg)。模型在内部测试集平均AUC为0.90±0.02,外部测试集平均AUC分别为0.84±0.12和0.87±0.11。

要点

  • 门静脉和肝静脉的全血管体积及长度在CSPH患者中显著减小。
  • 基于CT/MRI的血管几何模型对CSPH诊断具有良好一致性。
  • 该模型有望作为HVPG的无创替代方法用于肝硬化患者。

关键影像表现/征象

  • CSPH发生时门静脉全血管体积均值从36.9 cm3±16.0降至29.6 cm3±11.1(P<.05)。
  • CSPH发生时肝静脉全血管体积均值从35.3 cm3±21.5降至22.4 cm3±15.7(P<.05)。
  • CSPH患者门静脉全血管长度均值较无CSPH者短(1.7 m±1.2 vs 3.0 m±2.4,P<.05)。
  • CSPH患者肝静脉全血管长度均值较无CSPH者短(0.9 m±1.5 vs 1.8 m±1.5,P<.05)。

诊断标准与关键数值

  • CSPH定义为HVPG≥10 mm Hg。
  • 血管模型在内部测试集平均AUC为0.90±0.02。
  • 血管模型在外部测试集平均AUC分别为0.84±0.12和0.87±0.11。

临床应用与阅片要点

  • 在肝硬化患者CT/MRI阅片时,可关注门静脉和肝静脉的全血管体积及长度减小。
  • 血管几何模型可作为无创评估CSPH的辅助工具,减少HVPG测量的需要。
  • 需注意该模型基于特定血管参数提取,临床应用中应确保图像质量和分割准确性。

局限性

  • 回顾性研究设计。
  • 外部验证数据集样本量相对较小。
  • 模型依赖于血管参数提取,可能受图像质量和分割算法影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Currently, the hepatic venous pressure gradient (HVPG) remains the reference standard for diagnosis of clinically significant portal hypertension (CSPH) but is limited by its invasiveness and availability. Purpose To investigate a vascular geometric model for noninvasive diagnosis of CSPH (HVPG ≥10 mm Hg) in patients with liver cirrhosis for both contrast-enhanced CT and MRI. Materials and Methods In this retrospective study, consecutive patients with liver cirrhosis who underwent HVPG measurement from August 2016 to April 2019 were included. Patients without hepatic diseases were included and marked as non-CSPH to balance the ratio of CSPH 1:1. A variety of vascular parameters were extracted from the portal vein, hepatic vein, aorta, and inferior vena cava and then entered into a vascular geometric model for identification of CSPH. Diagnostic performance was assessed with the area under the receiver operating characteristic curve (AUC). Results The model was developed and tested with retrospective data from 250 patients with liver cirrhosis and 273 patients without clinical evidence of hepatic disease at contrast-enhanced CT examination, including 213 patients with CSPH (mean age, 49 years ± 12 [SD]; 138 women) and 310 patients without CSPH (mean age, 50 years ± 9; 177 women). For external validation, an MRI data set with 224 patients with cirrhosis (mean age, 49 years ± 10; 158 women) and a CT data set with 106 patients with cirrhosis (mean age, 53 years ± 12; 71 women) were analyzed. Significant reductions in mean whole-vessel volumes were observed in the portal vein (ranging from 36.9 cm3 ± 16.0 to 29.6 cm3 ± 11.1; P < .05) and hepatic vein (ranging from 35.3 cm3 ± 21.5 to 22.4 cm3 ± 15.7; P < .05) when CSPH occurred. Similarly, the mean whole-vessel lengths were shorter in patients with CSPH (portal vein: 1.7 m ± 1.2 vs 3.0 m ± 2.4, P < .05; hepatic vein: 0.9 m ± 1.5 vs 1.8 m ± 1.5, P < .05) than in those without CSPH. The proposed vascular model performed well in the internal test set (mean AUC, 0.90 ± 0.02) and external test sets (mean AUCs, 0.84 ± 0.12 and 0.87 ± 0.11). Conclusion A contrast-enhanced CT- and MRI-based vascular model was proposed with good diagnostic consistency for hepatic venous pressure gradient measurement. ClinicalTrials.gov registration nos. NCT03138915 and NCT03766880 © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Roldán-Alzate and Reeder in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Wang, Huang, Liu, et al. Diagnosis of Clinically Significant Portal Hypertension Using CT- and MRI-based Vascular Model. Radiology. 2023. PMID: 36719293. doi:10.1148/radiol.221648

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。